Massive Bio and ConcertAI have each introduced artificial intelligence (AI)-based systems aimed at supporting oncology clinical trials at the Summit for Clinical Operations Executives (SCOPE) 2026 conference in Orlando, Florida.
Massive Bio’s system, TrialRelay, is a physician-facing enrollment orchestration platform designed to prevent patients from being lost following clinical trial referrals, a phenomenon known as the ‘referral black hole’. Previously known as Clinical Network, the system is powered by TrialRouter AI, an agent that connects patients, physicians, sites and sponsors for clinical trials.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
“Every oncologist has experienced the referral black hole,” said Dr Arturo Loaiza-Bonilla, cofounder and chief medical AI officer of Massive Bio. “You refer a patient with urgency – and then silence. TrialRelay eliminates that anxiety. We provide the ‘UPS tracking number’ for the patient’s journey. No drops. No black holes.”
Meanwhile, ConcertAI’s system, called Accelerated Clinical Trials (ACT), integrates real-world and proprietary data with advanced AI workflows to help sponsors and contract research organisations (CROs) shorten overall trial timelines by 10 to 20 months, significantly reducing costs and bringing therapies to market faster. The system is built on CARAai ConcertAI’s proprietary agentic AI platform.
A study from the Tufts Center for the Study of Drug Development (CSDD) found that 76% of Phase I-IV trials require amendments. By leveraging AI-driven probability forecasts, ACT helps with trial design and operation to design studies that have a higher likelihood of meeting enrolment goals and delivering successful outcomes.
CEO of ConcertAI, Eron Kelly, said: “Trial inefficiencies come at a high cost – both financial and for patients awaiting new therapies. Sponsors don’t need another isolated tool; they need an end-to-end solution that identifies bottlenecks and guides next steps. With ACT, we deliver on the promise of agentic AI for life sciences, giving trial teams greater control and clear visibility throughout the entire study lifecycle.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAI taking centre stage
AI is increasingly embedded in clinical trials, particularly in recruitment, trial design and data analysis. At SCOPE 2026 alone, many sessions are examining its potential throughout all stages of clinical development.
Despite this, challenges to adoption remain including integration, regulation and the speed in which AI is developing.
There has been some progress in regulation, with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) releasing collaborative guidance on the use of AI in medicine development.
According to GlobalData, parent company of Clinical Trials Arena, venture financing deals involving AI have experienced more than a 400% increase between 2014 and 2024, showing how industry confidence is growing in the technology.
